<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>64474</routedMedId>
		<routedMedName>Forteo subcutaneous</routedMedName>
		<routedGenericName>teriparatide subcutaneous</routedGenericName>
		<etcIds>
			<etc_id>68240000</etc_id>
		</etcIds>
		<medIds>
			<medId>556442</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<?oxy_comment_start author="payaldesai" timestamp="20150205T135707-0800" comment="Per John, do DXID for now and capture High Risk For Fracture in assessments"?>
			<fqn><?oxy_comment_end?>Post-Menopausal Osteoporosis</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>f</gender>
			<icd9>22.2899</icd9>
			<symbolic>ostfemaleforteo</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name>high risk of fracture</name>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype>
				<name/>
			</subtype>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>not applicable</name>
					<code>not applicable</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<codeValues>02.16383|02.1257|02.154925|02.162097|02.92884|02.1273|02.92883|02.7835</codeValues>
								<selectedListName>oral bisphosphonates</selectedListName>
								<selectedListClassCode>16.01</selectedListClassCode>
								<dur>12</dur>
								<durUnit>months</durUnit>
								<durModifier>ge</durModifier>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
						</treatment>
						<treatment>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
							<treatmentLine>
								<option>AND</option>
								<interventionType>group</interventionType>
								<codeValues>02.95102|02.94907|02.148235|02.148199</codeValues>
								<selectedListName>intravenous bisphosphonates</selectedListName>
								<selectedListClassCode>16.02</selectedListClassCode>
								<dur>12</dur>
								<durUnit>months</durUnit>
								<durModifier>ge</durModifier>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion/>
			<dosing>
				<text>20 mg subcutaneously once a day</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<?oxy_comment_start author="payaldesai" timestamp="20150205T135325-0800" comment="Per discussion with team, represent multi dose team as such"?>
					<medId><?oxy_comment_end?>64474</medId>
					<initPerDayDesc/>
					<initPerIntervalDesc>1 pen (2.4 mL) per 28 days</initPerIntervalDesc>
					<renewPerDayDesc/>
					<renewPerIntervalDesc>1 pen (2.4 mL) per 28 days</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur>2</dur>
					<durUnit>y</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. http://nof.org/files/nof/public/content/file/2610/upload/895.pdf. Published April 1, 2014. Accessed August 1, 2014.</reference>
				<reference>Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-22. (Also available on the Endocrine Society’s website http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm)</reference>
				<reference>Kanis JA; for World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Published 2007.  Accessed August 1, 2014.</reference>
				<reference>Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2012</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
		</diagnosis>
		<diagnosis>
			<fqn>Hypogonadal Osteoporosis in Males</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>m</gender>
			<icd9>23.9027</icd9>
			<symbolic>ostmaleforteo</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								
							</treatmentLine>
						</treatment>
						<treatment>
							
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<codeValues>02.16383|02.1257|02.154925|02.162097|02.92884|02.1273|02.92883|02.7835</codeValues>
								<selectedListName>oral bisphosphonates</selectedListName>
								<selectedListClassCode>16.01</selectedListClassCode>
								<dur>12</dur>
								<durUnit>months</durUnit>
								<durModifier>ge</durModifier>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
						</treatment>
						<treatment>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
							<treatmentLine>
								<option>AND</option>
								<interventionType>group</interventionType>
								<codeValues>02.95102|02.94907|02.148235|02.148199</codeValues>
								<selectedListName>intravenous bisphosphonates</selectedListName>
								<selectedListClassCode>16.02</selectedListClassCode>
								<dur>12</dur>
								<durUnit>months</durUnit>
								<durModifier>ge</durModifier>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text>20 mg subcutaneously once a day</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>64474</medId>
					<initPerDayDesc/>
					<initPerIntervalDesc>1 pen (2.4 mL) per 28 days</initPerIntervalDesc>
					<renewPerDayDesc/>
					<renewPerIntervalDesc>1 pen (2.4 mL) per 28 days</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur>2</dur>
					<durUnit>y</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. http://nof.org/files/nof/public/content/file/2610/upload/895.pdf. Published April 1, 2014. Accessed August 1, 2014.</reference>
				<reference>Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-22. (Also available on the Endocrine Society’s website http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm)</reference>
				<reference>Kanis JA; for World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Published 2007.  Accessed August 1, 2014.</reference>
				<reference>Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2012</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			
		</diagnosis>
		<diagnosis>
			<fqn>Glucocorticoid Induced Osteoporosis</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2901</icd9>
			<symbolic/>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>oral bisphosphonates</name>
								<codeValues>02.16383|02.1257|02.154925|02.162097|02.1273|02.7835</codeValues>
								<selectedListName>16.01</selectedListName>
								<selectedListClassCode/>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name>zoledronic acid</name>
								<codeValues>01.113876| 01.113840</codeValues>
								<selectedListName>16.04</selectedListName>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text>20 mg subcutaneously once a day</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>64474</medId>
					<initPerDayDesc/>
					<initPerIntervalDesc>1 pen (2.4 mL) per 28 days</initPerIntervalDesc>
					<renewPerDayDesc/>
					<renewPerIntervalDesc>1 pen (2.4 mL) per 28 days</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur>2</dur>
					<durUnit>y</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. http://nof.org/files/nof/public/content/file/2610/upload/895.pdf. Published April 1, 2014. Accessed August 1, 2014.</reference>
				<reference>Kanis JA; for World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Published 2007.  Accessed August 1, 2014.</reference>
				<reference>Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2012</reference>
				<reference>Grossman JM, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care &amp; Research 2010;62(11):1515-26. DOI: 10.1002/acr.20295. (Reaffirmed 2013 Nov) </reference>
				<reference>Management of corticosteroid-induced osteoporosis. Drug and Therapeutics Bulletin 2010;48(9):98-101. DOI: 10.1136/dtb.2010.09.0047</reference>
				<reference>Karras D, et al. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. Journal of Rheumatology 2012;39(3):600-9</reference>
				<reference>Devogelaer JP, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. Journal of Rheumatology 2010;37(1):141-8</reference>
				<reference>Saag KG, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis and Rheumatism 2009;60(11):3346-55</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
		<listDef>
			<name>oral bisphosphonates</name>
			<codeValue>16.01</codeValue>
			<listType>adhoc</listType>
			<listItem>
				<name>Actonel oral</name>
				<codeValue>02.16383</codeValue>
			</listItem>
			<listItem>
				<name>alendronate oral</name>
				<codeValue>02.1257</codeValue>
			</listItem>
			<listItem>
				<name>Atelvia oral</name>
				<codeValue>02.154925</codeValue>
			</listItem>
			<listItem>
				<name>Binosto oral</name>
				<codeValue>02.162097</codeValue>
			</listItem>
			<listItem>
				<name>Boniva oral</name>
				<codeValue>02.92884</codeValue>
			</listItem>
			<listItem>
				<name>Fosamax oral</name>
				<codeValue>02.1273</codeValue>
			</listItem>
			<listItem>
				<name>ibandronate oral</name>
				<codeValue>02.92883</codeValue>
			</listItem>
			<listItem>
				<name>risedronate oral</name>
				<codeValue>02.7835</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>intravenous bisphosphonates</name>
			<codeValue>16.02</codeValue>
			<listType>adhoc</listType>
			<listItem>
				<name>Boniva intravenous</name>
				<codeValue>02.95102</codeValue>
			</listItem>
			<listItem>
				<name>ibandronate intravenous</name>
				<codeValue>02.94907</codeValue>
			</listItem>
			<listItem>
				<name>Reclast intravenous</name>
				<codeValue>02.148235</codeValue>
			</listItem>
			<listItem>
				<name>zoledronic acid in mannitol and water intravenous</name>
				<codeValue>02.148199</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>bisphosphonates</name>
			<codeValue>16.03</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Fosamax</name>
				<codeValue>01.1265</codeValue>
			</listItem>
			<listItem>
				<name>risedronate</name>
				<codeValue>01.7510</codeValue>
			</listItem>
			<listItem>
				<name>alendronate</name>
				<codeValue>01.1249</codeValue>
			</listItem>
			<listItem>
				<name>Actonel</name>
				<codeValue>01.15387</codeValue>
			</listItem>
			<listItem>
				<name>ibandronate</name>
				<codeValue>01.79193</codeValue>
			</listItem>
			<listItem>
				<name>zoledronic acid-mannitol-water</name>
				<codeValue>01.113840</codeValue>
			</listItem>
			<listItem>
				<name>Boniva</name>
				<codeValue>01.79194</codeValue>
			</listItem>
			<listItem>
				<name>Reclast</name>
				<codeValue>01.113876</codeValue>
			</listItem>
			<listItem>
				<name>Atelvia</name>
				<codeValue>01.124640</codeValue>
			</listItem>
			<listItem>
				<name>Binosto</name>
				<codeValue>01.197285</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>triedtherapyclasses</name>
			<codeValue>ttc</codeValue>
			<listType>internal</listType>
			<listItem>
				<name>bisphosphonates - excludes glucorticoid osteoporosis</name>
				<codeValue>16.03</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>zoledronic acid</name>
			<codeValue>16.04</codeValue>
			<listType>generic</listType>
			<listItem>
				<name>Reclast</name>
				<codeValue>01.113876</codeValue>
			</listItem>
			<listItem>
				<name>zoledronic acid-mannitol-water</name>
				<codeValue>01.113840</codeValue>
			</listItem>
		</listDef>
	</lists>
</paload>
